Nuvation Bio (NUVB) Competitors $2.25 +0.02 (+0.76%) Closing price 07/17/2025 03:59 PM EasternExtended Trading$2.27 +0.02 (+0.85%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVB vs. KYMR, MOR, HCM, RARE, ALVO, AMRX, MIRM, CPRX, ARWR, and IBRXShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Kymera Therapeutics (KYMR), MorphoSys (MOR), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Arrowhead Pharmaceuticals (ARWR), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. Its Competitors Kymera Therapeutics MorphoSys HUTCHMED Ultragenyx Pharmaceutical Alvotech Amneal Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals Arrowhead Pharmaceuticals ImmunityBio Nuvation Bio (NYSE:NUVB) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Is NUVB or KYMR more profitable? Kymera Therapeutics has a net margin of -409.07% compared to Nuvation Bio's net margin of -5,534.21%. Kymera Therapeutics' return on equity of -30.11% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-5,534.21% -44.14% -32.97% Kymera Therapeutics -409.07%-30.11%-25.65% Which has more volatility & risk, NUVB or KYMR? Nuvation Bio has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Do insiders & institutionals believe in NUVB or KYMR? 61.7% of Nuvation Bio shares are owned by institutional investors. 29.9% of Nuvation Bio shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher valuation & earnings, NUVB or KYMR? Kymera Therapeutics has higher revenue and earnings than Nuvation Bio. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M97.15-$567.94M-$2.35-0.96Kymera Therapeutics$47.07M64.12-$223.86M-$3.10-14.95 Does the media prefer NUVB or KYMR? In the previous week, Nuvation Bio had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 3 mentions for Nuvation Bio and 2 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.63 beat Nuvation Bio's score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate NUVB or KYMR? Nuvation Bio currently has a consensus target price of $7.17, indicating a potential upside of 218.94%. Kymera Therapeutics has a consensus target price of $59.11, indicating a potential upside of 27.53%. Given Nuvation Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Nuvation Bio is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryNuvation Bio and Kymera Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$758.79M$2.94B$5.56B$20.75BDividend YieldN/A2.45%3.80%3.67%P/E Ratio-0.9620.2928.0527.62Price / Sales97.15302.32437.8959.14Price / CashN/A43.1635.8422.13Price / Book1.647.838.254.66Net Income-$567.94M-$55.11M$3.24B$994.58M7 Day Performance2.14%3.21%1.45%0.00%1 Month Performance25.88%12.86%8.04%5.25%1 Year Performance-29.34%5.06%30.08%10.76% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio3.1707 of 5 stars$2.25+0.8%$7.17+218.9%-33.7%$758.79M$7.87M-0.9660KYMRKymera Therapeutics2.9738 of 5 stars$44.90+0.9%$59.11+31.7%-1.0%$2.92B$47.07M-14.48170MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730HCMHUTCHMED1.0322 of 5 stars$16.23+1.2%$19.00+17.1%-8.4%$2.83B$630.20M0.001,811Positive NewsRAREUltragenyx Pharmaceutical4.3899 of 5 stars$29.23-0.9%$83.64+186.2%-37.5%$2.76B$560.23M-4.971,294Trending NewsAnalyst RevisionHigh Trading VolumeALVOAlvotech2.716 of 5 stars$8.90+4.5%$18.00+102.2%-27.1%$2.68B$585.60M24.051,032AMRXAmneal Pharmaceuticals3.0972 of 5 stars$8.42+1.1%$11.60+37.8%+10.9%$2.64B$2.79B-210.458,100MIRMMirum Pharmaceuticals3.1303 of 5 stars$53.28+1.2%$65.50+22.9%+37.4%$2.64B$336.89M-33.09140CPRXCatalyst Pharmaceuticals4.9027 of 5 stars$21.62-0.9%$32.83+51.9%+26.9%$2.64B$491.73M13.7780Positive NewsARWRArrowhead Pharmaceuticals3.7581 of 5 stars$18.61+1.6%$43.71+134.9%-32.7%$2.57B$545.21M-13.29400Positive NewsIBRXImmunityBio2.3001 of 5 stars$2.90+3.2%$12.25+322.4%-53.8%$2.56B$31.22M-5.00590 Related Companies and Tools Related Companies Kymera Therapeutics Alternatives MorphoSys Alternatives HUTCHMED Alternatives Ultragenyx Pharmaceutical Alternatives Alvotech Alternatives Amneal Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives ImmunityBio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NUVB) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NUVB Stock Alerts